Soligenix CEO to make presentation at ROTH Conference
The company has been focusing on vaccination candidates for use in biological defense and preparedness efforts against ricin and anthrax -- RiVax and VeloThrax, respectively -- which were reported to have been effective in pre-clinical trials involving nonhuman primates. The company presented these findings at the American Society for Microbiology meeting last month.
Both vaccine candidates are supported by the company’s ThermoVax technology, which allows for long-term stockpiling and storage at room temperature. Both projects were supported with federal grants from the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.
Soligenix also has development projects in the area of therapeutics for inflammation and oncology, including a novel light-based treatment for T-cell lymphoma and a beclomethasone treatment for gastrointestinal conditions and disorders such as Crohn's disease.
The presentation is scheduled to take place at the Ritz Carlton Laguna Niguel at 1 p.m. PDT.